Dengue virus (DENV) causes a wide range of illnesses in humans: dengue fever (DF), dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Animal models that constantly develop high levels of viraemia are required for the development of protective and preventive measures. Common marmosets (Callithrix jacchus) demonstrated high levels of viraemia after inoculation with clinical isolates of four serotypes of DENV; in particular, over 10 6 genome copies ml "1 after inoculation with DENV-2. Non-structural protein 1 and DENV-specific IgM and IgG antibodies were consistently detected. The DENV-2 genome was detected in lymphoid organs including the lymph nodes, spleen and thymus, and also in non-lymphoid organs. DENV antigen was detected by immunohistochemistry in the liver and spleen from inoculated marmosets. Four marmosets were reinoculated with DENV-2 at 33 weeks after primary inoculation with DENV-2. The DENV-2 genome was not detected in any of these marmosets, indicating protection from a secondary infection. The results indicate that common marmosets are highly sensitive to DENV infection, and suggest that marmosets could be a reliable primate model for the evaluation of candidate vaccines.
INTRODUCTION
Dengue virus (DENV) is an arthropod-borne flavivirus and is a serious cause of morbidity and mortality in the world. Approximately 2.5 billion people living in tropical and subtropical areas are at risk of DENV infection. Infection with any one of the four serotypes of DENV (DENV1-4) causes a range of symptoms: classical dengue fever (DF), and the sometimes fatal dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). DF is an acute febrile illness, characterized by headache, rash, retro-orbital pain, arthralgia and myalgia. DHF is characterized by capillary leakage, thrombocytopenia, haemorrhagic manifestations, hypotension and liver parenchyma necrosis. When profound plasma leakage results in shock, the disease is called DSS (Halstead, 2007; WHO, 2002) . No vaccines or specific antiviral drugs are currently available.
Animal models of DENV could facilitate the development of vaccines and anti-dengue viral agents (Bente & RicoHesse, 2006) . Mouse models have proved to be useful in therapeutics and vaccine efficacy studies (Balsitis et al., 2010; Shrestha et al., 2010) . However, limitations of these models include the usage of immunocompromised mice and the development of only limited levels of viraemia in immunocompetent mice, even when high titres of DENV were inoculated. These aspects necessitate the development of immunocompetent animal models that are more relevant to DENV infection in humans, with the capability of supporting high levels of viral replication and antibody (Ab) response, and with additional advantages such as availability, ease of maintenance and handling. Nonhuman primates, rhesus monkeys, cynomolgus monkeys and owl monkeys, have been used in the evaluation of candidate vaccines (Koraka et al., 2007) ; however, not all non-human primate models develop overt levels of viraemia (Ito et al., 2010) . It has been reported that disease severity is related to high levels of viraemia, and, reduction in viraemia is associated with reduced disease severity (Libraty et al., 2002a) . Neutralizing antibodies play a key role in protection and is an indicator of protective immunity as well as vaccine efficacy. A suitable animal model that consistently develops high levels of viraemia would provide a useful tool in addressing fundamental issues regarding vaccine development.
As viraemia is a critical parameter in assessing vaccine efficacy, establishment of models with close evolutionary proximity to humans would offer a valuable tool. In the present study, we attempt to establish a new animal model of DENV infection using common marmosets (Callithrix jacchus). Common marmosets are a small New World monkey that could be maintained with relative ease in captivity as compared with many other non-human primates. Subcutaneous inoculation of common marmosets with DENV consistently induces high levels of viraemia and Ab response. Marmosets that received a secondary inoculation with DENV-2 at 33 weeks after the primary inoculation did not develop detectable levels of viraemia. The results suggest that marmosets are a potentially reliable DENV infection model for the development of vaccine and anti-DENV therapeutics.
RESULTS

Infection of marmosets with four serotypes of DENV
Marmosets were subcutaneously inoculated with clinical isolates of DENV: 3.5610 7 p.f.u. of DENV-1 (02-17/1 strain), 6.7610 7 p.f.u. of DENV-2 (DHF0663 strain), 4.5610 6 p.f.u. of DENV-3 (DSS1403 strain) and 1.5610 6 p.f.u. of DENV-4 (05-40/1 strain). The strains DENV-1 02-17/1, DENV-2 DHF0663, DENV-3 DSS1403 and DENV-4 05-40/1 were clinical isolates that were propagated for less than four passages on C6/36 cells. Levels of dengue viral RNA (dengue vRNA) were assessed in plasma at various time points (Table 1 , experiment 1). Dengue vRNA was detected in plasma samples from the marmosets on days 3 and 5 after inoculation. For each of the four animals (D1-1, D2-1, D3-1 and D4-1), the plasma levels of vRNA reached 5.0610 5 copies ml 21 on day 5, 1.6610 7 copies ml 21 on day 3, 5.5610 4 copies ml 21 on day 5 and 2.5610 4 copies ml 21 on day 3, respectively.
The level of non-structural protein 1 (NS1) in plasma samples was assessed by ELISA (Fig. 1a) . NS1 was detected in plasma samples from D1-1, D2-1 and D3-1, and peaked on days 3-10 for D1-1, and on day 3 for D2-1 and D3-1. The results demonstrated that DENV-2 induced high levels of viraemia, and DENV-2 was, thus, used in the next series of experiments.
Infection of marmosets with four different doses of DENV-2
Four marmosets were inoculated with DENV-2 (DHF0663 strain) at two different doses; D2-2 and D2-3 with 4.4610 7 p.f.u., and D2-4 and D2-5 with 1.8610 5 p.f.u. Dengue vRNA was detected at levels of 10 6 -10 7 copies ml 21 in plasma samples from all the marmosets on day 3 (Table 1 , experiment 2). NS1 antigen was also detected in plasma samples from all the marmosets (Fig. 1d) .
Four marmosets were then inoculated with lower doses of DENV-2 (DHF0663 strain); D2-6 and D2-7 with 1.8610 4 p.f.u., and D2-8 and D2-9 with 1.8610 3 p.f.u. Dengue vRNA was detected on days 2, 4 and 7 in all the four marmosets ( (Fig. 1g) . The results in experiments 2 and 3 indicate that marmosets inoculated with ¢1.8610 3 p.f.u. developed viraemia at levels of more than 3.7610 5 copies ml
21
.
Infection of marmosets with two other strains of DENV-2
Two other strains of DENV-2 were examined for the ability to induce viraemia. Marmosets D2-10 and D2-11 were inoculated with 1.2610 5 p.f.u. of Jam/77/07 strain, and D2-12 and D2-13 with 1.9610 5 p.f.u. of Mal/77/08 strain. The DENV-2 strains, Jam/77/07 and Mal/77/08, were clinical DENV strains that were propagated less than four passages on C6/36 cells. Dengue vRNA was detected in plasma samples from all four marmosets on days 2, 4 and 7, and the peak levels reached over 10 6 copies ml 21 on day 4 (Table 1, experiment 4). NS1 antigen was detected in plasma samples from all marmosets (Fig. 1j) . The results in experiments 2, 3 and 4 indicate that marmosets developed similarly high levels of viraemia after inoculation with three different strains of DENV-2.
Antibody responses in marmosets after inoculation with DENV DENV-specific IgM and IgG Ab responses were examined by ELISA after inoculation with DENV. In experiment 1, specific IgM Ab was first detected on day 5 for D1-1, D2-1 and D3-1, and, on day 7 for D4-1 (Fig. 1b) . IgM Ab reached peak levels on day 10 for D1-1, D2-1 and D3-1. IgG Ab was first detected on day 10 for all four animals, and IgG Ab levels increased thereafter (Fig. 1c) . Although DENV-4 inoculation induced only low levels of viraemia, both DENV-specific IgM and IgG Abs were induced. DENV-specific IgM and IgG were similarly detected in all the marmosets inoculated with DENV-2 in experiments 2, 3 and 4 (Fig. 1e , h, k for IgM, and Fig.  1f , i, l for IgG). These results, along with those shown in Table 1 and Fig. 1(b, c) , indicate that DENV propagated and induced specific IgM and IgG antibodies in marmosets.
Detection of DENV in organs
The distribution of DENV in organs was examined. Four marmosets were inoculated with 6.7610 7 p.f.u. of DENV-2 (DHF0663 strain). One animal each was euthanized and the organs collected on days 3, 5, 8 and 14. All marmosets demonstrated viraemia (Table 1 , experiment 5). NS1 antigen was also detected in all four marmosets (Fig. 1m ). IgM and IgG were first detected on day 5 and day 8, respectively (Fig. 1n, o) . The results indicate that DENV-2 infection was established in these four marmosets.
Levels of DENV-2 vRNA were assessed in thymus, lung, liver, kidneys, pancreas, spleen, lymph nodes, urinary 
The marmosets were sacrificed and no samples were collected. DIndicates day 15.
bladder and bone marrow on days 3, 5, 8 and 14 after inoculation (Table 2) . DENV-2 vRNA was detected in mandibular, axillary, mesenteric and inguinal lymph nodes from all animals. DENV-2 vRNA was detected in thymus on days 3, 5 and 8, and in spleen on days 5, 8 and 14. DENV-2 vRNA was also detected in the non-lymphoid ELISA index of NS1 antigen (a, d, g, j, m and p), P/N ratio of DENV-specific IgM Ab (b, e, h, k, n and q) and P/N ratio of DENVspecific IgG Ab (c, h, i, l, o and r) in plasma samples from marmosets inoculated with DENV in experiment 1 (a-c), experiment 2 (d-f), experiment 3 (g-i), experiment 4 (j-l), experiment 5 (m-o) and experiment 6 (p-r). Day 0 was defined as the day of virus inoculation.
Common marmoset as a model of dengue virus infection organs: lungs, liver, kidneys, pancreas and urinary bladder. The results suggest that DENV-2 propagated in the lymphoid organs and non-lymphoid organs.
The presence of DENV-infected cells was examined in the liver and spleen by immunohistochemistry. DENV antigen-positive cells were detected in Kupffer cells in the liver (Fig. 2a) and in lymphocytes and macrophages in the spleen (Fig. 2b) . The results confirm that DENV infection was established in marmosets after inoculation with DENV.
Absence of dengue vRNA after a secondary inoculation with DENV-2
Four marmosets (D2-2, D2-3, D2-4 and D2-5) were reinoculated with 1.8610 5 p.f.u. of DENV-2 at 33 weeks after primary inoculation with DENV-2. The levels of dengue vRNA were assessed on days 0, 2, 4, 7, 15 and 21 after the secondary inoculation (Table 1, experiment 6). Dengue vRNA was not detected in any of the marmosets on 2-21 days after inoculation. NS1 antigen was not detected in any of the four marmosets after secondary inoculation with DENV-2 (Fig. 1p) .
Robust IgG responses were detected by ELISA in all the four marmosets (Fig. 1r) . Neutralizing Ab was examined in the four marmosets (D2-2-D2-5) after the primary and secondary inoculations (Table 3, experiment 2). Neutralizing Ab was first detected on day 14 after the primary inoculation. Neutralizing Ab titres were at levels of 1 : 20-1 : 80 before the secondary inoculation. The titres increased from 1 : 160 to 1 : 640 on day 7 after the secondary inoculation (Table 3 , experiment 6). The results indicate that primary inoculation with DENV-2 induced protective immunity to DENV-2.
DISCUSSION
Non-human primates and rodents have been used as animal models for the evaluation of candidate dengue vaccines. Although Ab responses and kinetics of viraemia in these models, in particular in macaques, were similar to those in human DENV infection, viraemia levels were modest and apparent clinical signs were absent (Ito et al., 2010; Marchette et al., 1973) . There remains a need for the development of a reliable animal model that better recapitulates DENV infection in humans. Several aspects, including incubation period, duration of viraemia and Ab responses in experimentally infected marmosets in the present studies appear to recapitulate DENV infection in humans (Vaughn et al., 1997) .
DENV infection induces the NS1 antigen in blood (Alcon et al., 2002; Flamand et al., 1999; Libraty et al., 2002b) . As reported in human studies (Mackenzie et al., 1996) , the NS1 antigen was detected in DENV-infected marmosets, indicating DENV replication. Plasma viraemia levels reached a peak of approximately 10 6 copies ml 21 on day 4 followed by gradual decline, with inoculation as low as 10 3 p.f.u. of DENV. In addition, using a subset of samples, ).
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peak viraemia titres were examined in three marmosets using the plaque titration method. Peak viraemia titres were constantly detected on days 3 and 4 after infection. Viraemia titres were 1.0610 4 p.f.u. ml 21 (D2-6) and 1.0610 3 p.f.u. ml 21 (D2-12) at 4 days post-inoculation, and 8.3610 3 p.f.u. ml 21 (D2-14) at 3 days post-inoculation. Quantitative RT-PCR has proved to be useful in studies determining viraemia levels in other DENV animal models using rhesus macaque and mice (Bente et al., 2005; Onlamoon et al., 2010) . Viraemia levels in marmosets determined by using quantitative real-time PCR (RT-PCR) and plaque assays were higher or at similar levels to those reported in other non-human primates (Bernardo et al., 2008; Blair et al., 2006; Goncalvez et al., 2007; Guirakhoo et al., 2004; Raviprakash et al., 2008; Schiavetta et al., 2003; Whitehead et al., 2003) . In the present study, all marmosets developed viraemia using inoculation doses from 10 7 to 10 3 p.f.u. per dose.
Although there was a tendency toward the development of differential viraemia patterns between the marmosets inoculated with 10 7 -10 5 p.f.u. per dose and 10 4 -10 3 p.f.u. per dose, further evaluations are needed to define the viraemia patterns between the two groups. The results indicate that a higher dose of viral inoculum does not necessarily lead to higher viraemia titres or longer viraemia durations. Overall, the results indicate that DENV infection was established after primary inoculation in marmosets. DENV viraemia was consistently detected in all of the experimentally infected marmosets using various DENV Common marmoset as a model of dengue virus infection strains isolated from human clinical samples at several of the inoculation doses. The results indicate that marmosets possess high sensitivity to DENV and could be a viable animal model for the evaluation of vaccine candidates and anti-DENV drugs.
In common marmosets, dengue vRNA was detected in lymphoid organs, lymph nodes, spleen, thymus and bone marrow, and also in non-lymphoid organs. DENV antigenpositive cells were detected in the spleen and liver of infected marmosets as in human patients (Bhamarapravati et al., 1967; de Araú jo et al., 2009; Jessie et al., 2004; Rosen et al., 1999) . Dengue vRNA was also detected in urine samples from DENV-infected marmosets (data not presented), as reported in human infection (Mizuno et al., 2007; Poloni et al., 2010) . Of note, vRNA was detected in organs on day 14 when viraemia was no longer detected, as reported by other investigators (Marchette et al., 1973) . The results confirm propagation of DENV in inoculated marmosets.
Infection with one serotype of DENV induces life-long protective immunity to the same serotype in humans. Dengue vRNA and NS1 were not detected in plasma samples from marmosets that were reinoculated with DENV-2 at 33 weeks after primary inoculation (Table 1) .
The results indicate that protective immunity to the same serotype of DENV was induced by the primary infection as demonstrated in humans, and suggest that the marmoset model is potentially useful for evaluation of immunogenecity of candidate dengue vaccines. In contrast, using RT-PCR, viraemia was detected in all marmosets (D2-6, D2-7, D2-8 and D2-9) that were reinoculated with heterologous DENV serotypes (DENV-1 and DENV-3). Viraemia titres for D2-6 and D2-7 as assessed by RT-PCR were 5.1610 4 copies ml 21 and 1.3610 5 copies ml
21
, respectively, at day 7 post-inoculation with DENV-1, and viraemia titres for D2-8 and D2-9 were 3.8610 5 copies ml 21 and 3.2610 5 copies ml 21 , respectively, at day 7 post-inoculation with DENV-3 (M. L. Moi and others, unpublished data). Viraemia was not detected at day 7 after primary infection with DENV-1 and DENV-3 (Table 1) . Although the results suggest that higher viraemia titres may have been induced in marmosets after secondary infection with heterologous DENV serotypes as compared with primary DENV infection, further studies using a greater number of marmosets are needed to address the clinical and pathophysiological aspects of heterologous secondary infection in marmosets. While other non-human primate models developed similar viraemia levels as marmosets shown in the present study (Guirakhoo et al., 2004) , the common marmoset model offers several advantages over other models for their use in research. These include small size (250-450 g), ease and lower cost of maintenance, availability and ease of handling which allows the introduction of flexibility into experimental procedures. Thus, common marmosets, in which high levels of viraemia were consistently detected upon DENV infection, could potentially provide a reliable and valuable model for evaluation of antiviral therapeutics and candidate vaccines against DENV.
METHODS
Cells. Vero cells were cultured in minimum essential medium (MEM; Sigma) with 10 % heat-inactivated FBS (Gibco) at 37 uC in 5 % CO 2 . C6/36 cells were cultured in MEM with 10 % FBS and 1 % nonessential amino acids at 28 uC in 5 % CO 2 .
Virus. DENV type 1 (DENV-1), 02-17/1 strain, DENV type 2 (DENV-2), DHF0663 strain (GenBank accession no. AB189122), D2/Hu/Jamaica/ 77/2007NIID (Jam/77/07) strain and D2/Hu/Maldives/77/2008NIID (Mal/77/08) strain, DENV type 3 (DENV-3), DSS1403 strain (GenBank accession no. AB189125) and DENV type 4 (DENV-4), 05-40/1 strain, were used for inoculation studies. The DENV-1 02-17/1 strain was isolated from an imported DF case from Indonesia. The DENV-2 DHF0663 strain was isolated from a DHF case in Indonesia. The DENV-2 Jam/77/07 and Mal/77/08 strains were isolated from imported DF cases from Jamaica and Maldives, respectively. The DENV-3 DSS1403 strain was isolated from a DSS case in Indonesia. The DENV-4 05-40/1 strain was isolated from an imported DF case from the Philippines. All DENV strains isolated from clinical samples were propagated with C6/36 cells and were used within four passages. Culture supernatant from infected C6/36 cells was centrifuged at 800 g for 5 min to remove cell debris, and then stored at 280 uC until use.
Infection of marmosets with DENV. A total of 20 male marmosets, weighing 258-512 g, were used. Marmosets were purchased from Clea Japan Inc. and caged singly at 27±2 uC in 50±10 % humidity with a 12 h light-dark cycle (lighting from 7 : 00 to 19 : 00) at Tsukuba Primate Research Center, National Institute of Biomedical Innovation, Tsukuba, Japan. Animals were fed twice a day with a standard marmoset diet (CMS-1M; CLEA Japan) supplemented with fruit, eggs and milk. Water was given ad libitum. The animals were in a healthy condition and confirmed to be negative for anti-DENV antibodies prior to primary DENV inoculation.
In experiment 1, the sensitivity of marmosets to each of the four serotypes of DENV was examined. Four marmosets were inoculated subcutaneously on the back with 3.5610 7 p.f.u. of DENV-1 (02-17/1 strain), 6.7610 7 p.f.u. of DENV-2 (DHF0663 strain), 4.5610 6 p.f.u. of DENV-3 (DSS1403 strain) or 1.5610 6 p.f.u. of DENV-4 (05-40/1 strain). Blood samples were collected before inoculation (day 0) and on days 3, 7, 10 and 14 after inoculation. Blood samples were used for the assessment of viraemia levels, IgG and IgM Abs, and the NS1 antigen level. All marmosets were euthanized on day 14 and organs were subjected to pathological examination.
In experiment 2, four marmosets were inoculated with DENV-2; two (D2-2 and D2-3) with 4.4610 7 p.f.u. of DENV-2, DHF0663 strain, and two (D2-4 and D2-5) with 1.8610 5 p.f.u. of DENV-2, DHF0663 strain. Blood samples were collected before inoculation (day 0) and on days 3, 7, 14 and 21 for the assessment of viraemia levels, IgG, IgM and the NS1 levels, and neutralizing Ab titres.
In experiment 3, four marmosets were used for the evaluation of their sensitivity to lower doses of DENV-2, DHF0663 strain; two (D2-6 and D2-7) with 1.8610 4 p.f.u., and two (D2-8 and D2-9) with 1.8610 3 p.f.u.
In experiment 4, four marmosets were inoculated with two other strains of DENV-2; two (D2-10 and D2-11) with 1.2610 5 p.f.u. of Jam/77/07 strain, and two (D2-12 and D2-13) with 1.9610 5 p.f.u. of Mal/77/08 strain. In these two experiments, blood samples were collected before inoculation (day 0) and on days 2, 4, 7, 14 and 21 for the assessment of viraemia levels, IgG, IgM and the NS1 levels.
In experiment 5, the distribution of DENV in various organs was examined. Four marmosets were inoculated with 6.7610 7 p.f.u. of DENV-2, DHF0663 strain. One each was euthanized on days 3, 5, 8 or 14 after inoculation, and the organs collected for detection of dengue vRNA and histopathological analysis. Blood samples were collected from the animals before inoculation (day 0) and on days 2, 4, 7 and 13 for virus titration, IgG, IgM and the NS1 antigen detection.
In experiment 6, four marmosets used in experiment 2 were reinoculated with 1.8610 5 p.f.u. of DENV-2, DHF0663 strain. Blood samples were collected on the day before inoculation (day 0) and on days 2, 4, 7, 15 and 21 for the assessment of viraemia levels and neutralizing Ab titres. Inoculation with DENV and blood drawing were performed under anaesthesia with 5 mg kg 21 of ketamine hydrochloride. Day 0 was defined as the day of virus inoculation.
All animal studies were conducted in accordance with 'Guides for animal experiments performed at National Institute of Infectious Diseases' approved by the Animal Welfare and Animal Care Committee of the National Institute of Infectious Diseases, Japan (approval nos 608011 and 609014), and 'National Institute of Biomedical Innovation rules and guidelines for experimental animal welfare' approved by the National Institute of Biomedical Innovation, Japan (approval nos 20-003 and 21-013).
Titration of vRNA in plasma and organs. Plasma samples were stored at 280 uC until use. Collected organs were homogenized by BioMasher (Nippi). Homogenized samples were suspended with 0.5 ml PBS(2) and centrifuged at 800 g for 5 min. After centrifugation, supernatants were collected and stored at 280 uC until use. vRNA was isolated from plasma and organ samples, using the High Pure Viral RNA kit (Roche Diagnostics). As housekeeping genes vary among tissues, experimental treatment and infection, total RNA was used to avoid specific expression profiles among housekeeping genes. Levels of dengue vRNA were determined by quantitative real-time RT-PCR as previously reported (Ito et al., 2004) . All RT-PCR assays were performed in duplicate.
Detection of DENV NS1, anti-DENV IgM and IgG Abs in plasma.
Levels of NS1 in plasma samples were assessed by Platelia Dengue NS1 Ag assay (Bio-Rad). The assay was performed according to the manufacturer's instructions with modification to the applied volume of plasma. ELISA index was calculated by the formula: optical density (OD) of the test sample divided by the mean OD of the cut-off control (tested in duplicate). ELISA indexes of ,1 and ¢1 were considered to be negative and positive, respectively. DENV-specific IgM Ab was detected by Dengue Fever IgM Capture ELISA (Focus) and DENV-specific IgG Ab was examined by Dengue IgG Indirect ELISA (PanBio) according to the manufacturer's instructions. The positive/negative (P/N) ratio was calculated by the formula: OD of the test sample divided by the OD of a negative sample. Plasma samples collected on the day of inoculation were used as the negative samples. P/N ratios of ,2 and ¢2 were considered to be negative and positive, respectively. All ELISAs were conducted in duplicates (Moi et al., 2010a) .
Titration of neutralizing Abs to DENV-2. Neutralizing Ab titres were determined by using plaque reduction neutralization tests with DENV-2, DHF0663 strain. Heat-inactivated serum samples were serially diluted twofold from 1 : 20 to 1 : 1250 with MEM supplemented with 2 % FCS. Virus-Ab mixture was prepared by mixing 50 ml DENV-2 at titres of 1000 p.f.u. ml 21 with 50 ml of serially diluted serum samples. Control virus samples were prepared by mixing 50 ml DENV-2 at titres of 1000 p.f.u. ml 21 with 50 ml MEM supplemented with 2 % FCS. Virus-Ab mixture was incubated at 37 uC for 1 h. One hundred microlitres of virus-Ab mixture was inoculated onto Vero monolayers into six-well plates. After 5 days of inoculation, cells were fixed and stained, and plaques were counted. Neutralization titre is expressed as the maximum dilution of plasma sample that yielded a .50 % plaque reduction in the virus inoculum as compared with control virus sample (Moi et al., 2010b) .
Immunohistochemical analysis. The livers and spleens from marmosets were fixed in 10 % neutral buffered formalin and embedded in paraffin. Paraffin-embedded tissues were cut into 4 mm sections. For immunohistochemical analysis, a series of sections was stained for DENV antigen using a marmoset polyclonal anti-DENV Ab conjugated with horseradish peroxidase. Sections were counterstained with haematoxylin.
